Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The NHS Innovation Accelerator call for 2024 is now open in England

NHS Innovation Accelerator (NIA) is an NHS England Accelerated Access Collaborative initiative delivered in partnership with Academic Health Science Networks, hosted at UCLPartners. The NIA’s mission is to spearhead the national acceleration of innovation and business growth of health and care innovators (‘Fellows’). The NIA program provides a range of support in response to the needs of each Fellow and the barriers to uptake of their innovation faces within the NHS. This includes a bespoke learning program, mentorship, and networking opportunities to equip Fellows with critical knowledge, relationships, and skills to scale innovation in the NHS.

On September 12, 2023, an application window was opened to join the NIA program in 2024. The application can be submitted by individuals from any background, including industry (SME), clinicians, and academia, with innovations of any type that solve a problem for the NHS. 

The innovation should meet the following conditions:

  • In use in at least one site in the NHS or elsewhere;
  • Supported by an evidence base and able to demonstrate better patient and/or staff outcomes;
  • Ready to spread across the NHS;
  • Led by an applicant who is open to learning and sharing insights.

NIA is recruiting for innovations that address specific themes, including cancer, respiratory disease/asthma, diabetes, hypertension/cardiovascular disease, and epilepsy.

The deadline for applications is October 22, 2023.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.